Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials

Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β pathways play an important role in the development and function of the TME, contributing to the immunos...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 905520
Main Authors Li, Linwei, Wen, Qinglian, Ding, Ruilin
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 26.07.2022
Subjects
immunotherapy
Oncology
PD-1
review
TGF-β
tumor microenvironment
VEGF
Online AccessGet full text

Cover

Abstract Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β pathways play an important role in the development and function of the TME, contributing to the immunosuppressive status of TME. To inhibit VEGF and/or TGF-β pathways can restore TME from immunosuppressive to immune-supportive status and enhance sensitivity to immunotherapy such as programmed death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. In this review, we described the existing preclinical and clinical evidence supporting the use of anti-VEGF and/or anti-TGF-β therapies to enhance cancer immunotherapy. Encouragingly, adopting anti-VEGF and/or anti-TGF-β therapies as a combination treatment with anti-PD-(L)1 therapy have been demonstrated as effective and tolerable in several solid tumors in clinical trials. Although several questions need to be solved, the clinical value of this combination strategy is worthy to be studied further.
AbstractList Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β pathways play an important role in the development and function of the TME, contributing to the immunosuppressive status of TME. To inhibit VEGF and/or TGF-β pathways can restore TME from immunosuppressive to immune-supportive status and enhance sensitivity to immunotherapy such as programmed death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. In this review, we described the existing preclinical and clinical evidence supporting the use of anti-VEGF and/or anti-TGF-β therapies to enhance cancer immunotherapy. Encouragingly, adopting anti-VEGF and/or anti-TGF-β therapies as a combination treatment with anti-PD-(L)1 therapy have been demonstrated as effective and tolerable in several solid tumors in clinical trials. Although several questions need to be solved, the clinical value of this combination strategy is worthy to be studied further.
Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β pathways play an important role in the development and function of the TME, contributing to the immunosuppressive status of TME. To inhibit VEGF and/or TGF-β pathways can restore TME from immunosuppressive to immune-supportive status and enhance sensitivity to immunotherapy such as programmed death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. In this review, we described the existing preclinical and clinical evidence supporting the use of anti-VEGF and/or anti-TGF-β therapies to enhance cancer immunotherapy. Encouragingly, adopting anti-VEGF and/or anti-TGF-β therapies as a combination treatment with anti-PD-(L)1 therapy have been demonstrated as effective and tolerable in several solid tumors in clinical trials. Although several questions need to be solved, the clinical value of this combination strategy is worthy to be studied further.Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β pathways play an important role in the development and function of the TME, contributing to the immunosuppressive status of TME. To inhibit VEGF and/or TGF-β pathways can restore TME from immunosuppressive to immune-supportive status and enhance sensitivity to immunotherapy such as programmed death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. In this review, we described the existing preclinical and clinical evidence supporting the use of anti-VEGF and/or anti-TGF-β therapies to enhance cancer immunotherapy. Encouragingly, adopting anti-VEGF and/or anti-TGF-β therapies as a combination treatment with anti-PD-(L)1 therapy have been demonstrated as effective and tolerable in several solid tumors in clinical trials. Although several questions need to be solved, the clinical value of this combination strategy is worthy to be studied further.
Author Ding, Ruilin
Li, Linwei
Wen, Qinglian
AuthorAffiliation 1 Department of Oncology, Affiliated Hospital of Southwest Medical University , Luzhou , China
2 Institute of Drug Clinical Trial/GCP Center, Affiliated Hospital of Southwest Medical University , Luzhou , China
AuthorAffiliation_xml – name: 2 Institute of Drug Clinical Trial/GCP Center, Affiliated Hospital of Southwest Medical University , Luzhou , China
– name: 1 Department of Oncology, Affiliated Hospital of Southwest Medical University , Luzhou , China
Author_xml – sequence: 1
  givenname: Linwei
  surname: Li
  fullname: Li, Linwei
– sequence: 2
  givenname: Qinglian
  surname: Wen
  fullname: Wen, Qinglian
– sequence: 3
  givenname: Ruilin
  surname: Ding
  fullname: Ding, Ruilin
BookMark eNp1kc1uEzEUhS1UREvpnqWXZTGpf8YzYxZIqDShUiRYRIid5bGvE1cTO3icSn0tHoRnwpO0UouEN9fyPefztc9bdBJiAITeUzLjvJNXLgYzY4SxmSRCMPIKnTHG60rW_OfJs_0puhjHO1JWIwgl_A065UKKtuvEGQqrDSS9g332Bmed1pB9WOPo8I-bxRzrYK9iwqvFvPrzG-eIIWx0MFAa2Vffv1SXyw8U5wPj4SMuMAz33sIkcSlusRl88EYPOCevh_Edeu1KgYvHeo5W85vV9ddq-W1xe_15WZmay1y5TjJqOsecbFrS2K6zhHdauNp2rYO61kz2VrQ146ZnjPaC2p6CZaClIZKfo9sj1kZ9p3bJb3V6UFF7dTiIaa10Ki8eQBnZOOpaLp1ltSi3CELK57BGC06YZoX16cja7fstWAMhJz28gL7sBL9R63ivJG-IOAxz-QhI8dcexqy2fjQwDDpA3I-KtYTRVlLRFGlzlJoUxzGBU8ZnnX2cyH5QlKgpejVFr6bo1TH6YiT_GJ_m-6_lLwJAsd0
CitedBy_id crossref_primary_10_1007_s12672_025_01989_3
crossref_primary_10_3389_fcvm_2023_1182334
crossref_primary_10_3390_biomedicines12112541
crossref_primary_10_1186_s12943_024_02183_9
crossref_primary_10_1186_s12964_024_01857_7
crossref_primary_10_3389_fonc_2023_1254694
crossref_primary_10_3390_cancers16061202
crossref_primary_10_1158_1078_0432_CCR_23_1829
Cites_doi 10.1056/NEJMoa1816047
10.1136/jitc-2019-000433
10.1016/s1470-2045(20)30533-7
10.1200/jco.21.00939
10.1056/NEJMoa2026982
10.1016/j.jtho.2020.11.026
10.1016/j.ccr.2005.10.012
10.1016/j.ejca.2020.06.007
10.1038/nrclinonc.2018.9
10.1016/j.canlet.2009.06.035
10.1016/j.lungcan.2021.08.006
10.1158/0008-5472.can-12-2325
10.4049/jimmunol.174.9.5215
10.1158/1078-0432.ccr-19-3806
10.1007/s12026-017-8944-9
10.1007/s00280-019-03979-z
10.1186/s12943-019-0974-6
10.1038/s42003-021-02191-1
10.1016/s1470-2045(18)30081-0
10.1200/jco.21.00306
10.1136/jitc-2020-000696
10.3390/molecules25173900
10.1016/j.jtho.2020.10.002
10.1200/jco.19.02394
10.1056/NEJMoa2035716
10.1016/s1470-2045(21)00252-7
10.1002/1878-0261.13146
10.1200/jco.2016.67.2477
10.1136/jitc-2020-001126
10.1038/sj.bjc.6604965
10.1158/1078-0432.ccr-21-1698
10.1038/nrclinonc.2018.29
10.1172/jci.insight.85974
10.1042/cs20201236
10.1016/j.lfs.2020.117580
10.1136/jitc-2020-000564
10.1016/j.jtho.2020.10.004
10.1016/j.annonc.2021.08.1218
10.1038/nm863
10.1016/j.annonc.2021.08.1484
10.1016/j.immuni.2019.03.024
10.1056/NEJMoa1716948
10.1200/JCO.2022.40.4_suppl.568
10.1016/j.lfs.2020.118163
10.1200/JCO.2021.39.15_suppl.9055
10.1097/CJI.0b013e318189f13c
10.3390/ijms19102900
10.1016/j.clgc.2021.04.007
10.1182/blood-2002-07-1956
10.1016/s1470-2045(18)30107-4
10.1200/jco.19.01598
10.1126/scisignal.aad1884
10.1158/2326-6066.cir-19-0360
10.3390/ijms22147575
10.1186/s12903-021-01890-9
10.2147/cmar.s216605
10.1200/jco.19.02627
10.1016/j.ctrv.2017.11.008
10.1016/j.bmc.2021.116038
10.1080/21645515.2017.1327107
10.1136/jitc-2020-000664
10.1136/jitc-2020-002068
10.1155/2014/638747
10.1200/JCO.2022.40.6_suppl.289
10.1080/2162402x.2016.1232222
10.3390/cancers10060194
10.1007/s40259-018-0303-4
10.1136/jitc-2021-003831
10.1038/ncomms12624
10.1016/j.immuni.2011.04.019
10.1001/jamaoncol.2019.3343
10.1186/s40425-018-0403-1
10.1016/j.ccell.2014.10.006
10.1136/jitc-2020-001395
10.1186/s40425-018-0420-0
10.1158/1078-0432.ccr-20-2571
10.1158/0008-5472.can-17-2176
10.1093/annonc/mdy454
10.1038/ni.2388
10.1016/j.annonc.2021.08.1880
10.4049/jimmunol.160.3.1224
10.1016/s1470-2045(20)30271-0
10.1200/jco.20.01920
10.1080/2162402x.2020.1811605
10.1084/jem.20140559
10.1080/14728222.2020.1744568
10.1016/s0140-6736(19)30723-8
10.1158/1078-0432.ccr-21-1504
10.1158/2326-6066.cir-18-0310
10.1158/1078-0432.ccr-17-2653
10.1200/jco.20.00808
10.1200/jco.21.02091
10.1200/JCO.2021.39.15_suppl.2503
10.1084/jem.193.2.f5
10.1161/circresaha.107.167171
10.1136/jitc-2020-000798
10.1111/cei.12069
10.1016/j.jtho.2020.03.003
10.1634/theoncologist.2020-0249
10.1056/NEJMoa2108330
10.1038/nature25501
10.1136/jitc-2021-SITC2021.427
10.1111/1348-0421.12586
10.1056/NEJMoa1915745
10.1038/s41467-017-02696-6
10.1002/jcp.21706
10.1038/s41416-018-0297-1
10.3389/fimmu.2021.778978
ContentType Journal Article
Copyright Copyright © 2022 Li, Wen and Ding.
Copyright © 2022 Li, Wen and Ding 2022 Li, Wen and Ding
Copyright_xml – notice: Copyright © 2022 Li, Wen and Ding.
– notice: Copyright © 2022 Li, Wen and Ding 2022 Li, Wen and Ding
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fonc.2022.905520
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_c96f1f739fd24503850095726a5302a2
PMC9360509
10_3389_fonc_2022_905520
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c439t-f8921c8f2f96706d88d038a5f4d87fe44a29bd57423cb221b51db1ed2ea9c093
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 00:46:21 EDT 2025
Thu Aug 21 17:59:07 EDT 2025
Fri Jul 11 17:00:35 EDT 2025
Tue Jul 01 00:47:37 EDT 2025
Thu Apr 24 23:09:09 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c439t-f8921c8f2f96706d88d038a5f4d87fe44a29bd57423cb221b51db1ed2ea9c093
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Camillo Porta, University of Bari Aldo Moro, Italy
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work and share last authorship
Reviewed by: Mototsugu Oya, Keio University, Japan; Mónica Bequet-Romero, Center for Genetic Engineering and Biotechnology (CIGB), Cuba
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2022.905520
PMID 35957885
PQID 2702179156
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_c96f1f739fd24503850095726a5302a2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9360509
proquest_miscellaneous_2702179156
crossref_citationtrail_10_3389_fonc_2022_905520
crossref_primary_10_3389_fonc_2022_905520
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-07-26
PublicationDateYYYYMMDD 2022-07-26
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-26
  day: 26
PublicationDecade 2020
PublicationTitle Frontiers in oncology
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Esebanmen (B31) 2017; 65
Sasikumar (B88) 2021; 4
Moore (B81) 2021; 39
Taylor (B55) 2020; 38
Socinski (B62) 2018; 378
Strauss (B99) 2020; 8
Amin (B60) 2018; 6
Donkor (B38) 2011; 35
Khan (B27) 2018; 15
Dudek (B49) 2020; 38
Bex (B83) 2022; 40
Lan (B76) 2020; 38
Sasikumar (B89) 2018; 32
Liu (B104) 2021; 39
Chowdhury (B61) 2021; 19
Mariathasan (B44) 2018; 554
Atkins (B51) 2018; 19
Ren (B68) 2021; 22
Kawazoe (B71) 2020; 21
Terme (B26) 2013; 73
Yoo (B102) 2020; 8
Ferrari (B46) 2009; 219
Gulley (B12) 2022; 16
Marcoe (B32) 2012; 13
Yap (B92) 2021; 27
Yasuda (B41) 2013; 172
Zhou (B66) 2021; 160
Shi (B105) 2021; 39
Finn (B67) 2020; 382
Chu (B65) 2021; 16
Strauss (B97) 2018; 24
Makker (B72) 2020; 38
Batlle (B35) 2019; 50
Tohyama (B54) 2014; 2014
Bang (B64) 2020; 137
Jain (B6) 2014; 26
Alfaro (B19) 2009; 100
Rini (B48) 2019; 393
Dahmani (B10) 2018; 10
Fukumura (B5) 2018; 15
Wu (B43) 2019; 120
Jung (B95) 2020; 85
Xu (B75) 2022; 40
Wu (B87) 2021; 33
Greco (B94) 2020; 9
Lind (B96) 2020; 8
Chau (B53) 2020; 12
Feng (B106) 2021; 32
Qu (B59) 2021; 27
Ohm (B21) 2003; 101
B103
Voron (B22) 2015; 212
Xie (B79) 2020; 8
Thomas (B37) 2005; 8
Makker (B73) 2022; 386
Sadeghzadeh (B17) 2020; 254
van den Bulk (B29) 2021; 135
Xu (B70) 2021; 27
Liu (B77) 2020; 8
Yi (B7) 2019; 18
Haque (B90) 2017; 13
Ferris (B15) 2018; 63
Eissler (B4) 2016; 5
Rocconi (B93) 2020; 21
de Almeida (B23) 2020; 8
Cui (B84) 2021; 12
Courau (B13) 2016; 1
Finn (B69) 2020; 38
Melisi (B91) 2021; 9
Xia (B74) 2022; 10
Wilson (B16) 2010; 288
Oyama (B18) 1998; 160
Xie (B110) 2022; 40
Meder (B42) 2018; 78
Doi (B100) 2020; 25
Choueiri (B9) 2018; 19
Moo-Young (B40) 2009; 32
Guo (B1) 2020; 258
Ning (B25) 2012; 125
Liu (B107) 2021; 32
Motzer (B52) 2019; 380
Roncarolo (B30) 2001; 193
Wallin (B8) 2016; 7
Rujirachotiwat (B28) 2021; 21
Choueiri (B57) 2021; 384
Coward (B86) 2021; 9
Feng (B108) 2021; 32
Friedman (B82) 2020; 8
Furukawa (B2) 2020; 25
Eshima (B36) 2018; 62
Xiong (B85) 2018; 19
Larson (B109) 2020; 24
Paz-Ares (B11) 2020; 15
Curiel (B20) 2003; 9
Gross-Goupil (B50) 2018; 29
Tada (B24) 2018; 6
Fan (B78) 2021; 16
Ravi (B14) 2018; 9
Ahmadzadeh (B39) 2005; 174
Cho (B98) 2020; 8
Liu (B80) 2019; 5
Kang (B101) 2020; 26
Motzer (B56) 2021; 384
Daud (B3) 2016; 34
Chung (B47) 2021; 22
Viel (B33) 2016; 9
Holderfield (B45) 2008; 102
Gonzalez-Junca (B34) 2019; 7
Pal (B58) 2021; 39
Herbst (B63) 2021; 16
References_xml – volume: 380
  year: 2019
  ident: B52
  article-title: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1816047
– volume: 8
  year: 2020
  ident: B96
  article-title: Dual targeting of tgf-B and pd-L1 Via a bifunctional anti-Pd-L1/Tgf-Brii agent: Status of preclinical and clinical advances
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2019-000433
– volume: 21
  year: 2020
  ident: B93
  article-title: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage Iii/Iv ovarian cancer (Vital): A randomised, double-blind, placebo-controlled, phase 2b trial
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(20)30533-7
– volume: 39
  year: 2021
  ident: B58
  article-title: Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: Results from the cosmic-021 study
  publication-title: J Clin Oncol
  doi: 10.1200/jco.21.00939
– volume: 384
  year: 2021
  ident: B57
  article-title: Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa2026982
– volume: 16
  year: 2021
  ident: B65
  article-title: Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced nsclc
  publication-title: J Thorac Oncol Off Publ Int Assoc Study Lung Cancer
  doi: 10.1016/j.jtho.2020.11.026
– volume: 8
  year: 2005
  ident: B37
  article-title: Tgf-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.10.012
– volume: 137
  year: 2020
  ident: B64
  article-title: Ramucirumab and durvalumab for previously treated, advanced non-Small-Cell lung cancer, Gastric/Gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/B study (Jvdj)
  publication-title: Eur J Cancer (Oxford Engl 1990)
  doi: 10.1016/j.ejca.2020.06.007
– volume: 15
  year: 2018
  ident: B27
  article-title: Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2018.9
– volume: 288
  year: 2010
  ident: B16
  article-title: Cathepsin G-mediated enhanced tgf-beta signaling promotes angiogenesis Via upregulation of vegf and mcp-1
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2009.06.035
– volume: 160
  year: 2021
  ident: B66
  article-title: Anlotinib combined with anti-Pd-1 antibody, camrelizumab for advanced nsclcs after multiple lines treatment: An open-label, dose escalation and expansion study
  publication-title: Lung Cancer (Amsterdam Netherlands)
  doi: 10.1016/j.lungcan.2021.08.006
– volume: 73
  year: 2013
  ident: B26
  article-title: Vegfa-vegfr pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.can-12-2325
– volume: 174
  year: 2005
  ident: B39
  article-title: Tgf-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory Cd8 T cells
  publication-title: J Immunol (Baltimore Md 1950)
  doi: 10.4049/jimmunol.174.9.5215
– volume: 26
  year: 2020
  ident: B101
  article-title: Safety and tolerability of bintrafusp Alfa, a bifunctional fusion protein targeting tgfβ and pd-L1, in Asian patients with pretreated recurrent or refractory gastric cancer
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
  doi: 10.1158/1078-0432.ccr-19-3806
– volume: 65
  year: 2017
  ident: B31
  article-title: The role of tgf-beta signaling in dendritic cell tolerance
  publication-title: Immunol Res
  doi: 10.1007/s12026-017-8944-9
– volume: 85
  year: 2020
  ident: B95
  article-title: Population pharmacokinetics of vactosertib, a new tgf-B receptor type I inhibitor, in patients with advanced solid tumors
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-019-03979-z
– volume: 18
  start-page: 60
  year: 2019
  ident: B7
  article-title: Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-0974-6
– volume: 4
  start-page: 699
  year: 2021
  ident: B88
  article-title: Pd-1 derived Ca-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
  publication-title: Commun Biol
  doi: 10.1038/s42003-021-02191-1
– volume: 19
  year: 2018
  ident: B51
  article-title: Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(18)30081-0
– volume: 39
  year: 2021
  ident: B81
  article-title: Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage iii or iv ovarian cancer: Placebo-controlled randomized phase iii trial (Imagyn050/Gog 3015/Engot-Ov39)
  publication-title: J Clin Oncol
  doi: 10.1200/jco.21.00306
– volume: 8
  year: 2020
  ident: B77
  article-title: Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: An open-label phase ii trial
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000696
– volume: 25
  start-page: 3900
  year: 2020
  ident: B2
  article-title: Interaction between immunotherapy and antiangiogenic therapy for cancer
  publication-title: Mol (Basel Switzerland)
  doi: 10.3390/molecules25173900
– volume: 16
  start-page: 299
  year: 2021
  ident: B78
  article-title: Camrelizumab plus apatinib in extensive-stage sclc (Passion): A multicenter, two-stage, phase 2 trial
  publication-title: J Thorac Oncol Off Publ Int Assoc Study Lung Cancer
  doi: 10.1016/j.jtho.2020.10.002
– volume: 38
  year: 2020
  ident: B49
  article-title: Phase Ib/Ii clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: Btcrc-Gu14-003
  publication-title: J Clin Oncol
  doi: 10.1200/jco.19.02394
– volume: 384
  year: 2021
  ident: B56
  article-title: Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa2035716
– volume: 22
  year: 2021
  ident: B68
  article-title: Sintilimab plus a bevacizumab biosimilar (Ibi305) versus sorafenib in unresectable hepatocellular carcinoma (Orient-32): A randomised, open-label, phase 2-3 study
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(21)00252-7
– volume: 16
  year: 2022
  ident: B12
  article-title: Dual inhibition of tgf-B and pd-L1: A novel approach to cancer treatment
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.13146
– volume: 125
  year: 2012
  ident: B25
  article-title: Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma
  publication-title: Chin Med J
– volume: 34
  year: 2016
  ident: B3
  article-title: Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2016.67.2477
– volume: 8
  year: 2020
  ident: B82
  article-title: Phase ii study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001126
– volume: 100
  year: 2009
  ident: B19
  article-title: Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of vegf on human dendritic cell differentiation from monocytes
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604965
– volume: 27
  year: 2021
  ident: B59
  article-title: Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: Data from an open-label, multicenter phase ii basket study
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.ccr-21-1698
– volume: 15
  year: 2018
  ident: B5
  article-title: Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2018.29
– volume: 1
  year: 2016
  ident: B13
  article-title: Tgf-B and vegf cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.85974
– volume: 135
  start-page: 35
  year: 2021
  ident: B29
  article-title: Therapeutic targeting of tgf-B in cancer: Hacking a master switch of immune suppression
  publication-title: Clin Sci (London Engl 1979)
  doi: 10.1042/cs20201236
– volume: 254
  year: 2020
  ident: B17
  article-title: Dendritic cell therapy in cancer treatment; the state-of-the-Art
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.117580
– volume: 8
  year: 2020
  ident: B102
  article-title: Phase I study of bintrafusp Alfa, a bifunctional fusion protein targeting tgf-B and pd-L1, in patients with pretreated biliary tract cancer
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000564
– volume: 16
  year: 2021
  ident: B63
  article-title: Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive nsclc
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.10.004
– volume: 32
  start-page: S753
  year: 2021
  ident: B106
  article-title: 776p shr-1701, a bifunctional fusion protein targeting pd-L1 and tgf-B, for pretreated advanced cervical cancer: Data from a clinical expansion cohort of a phase I study
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.08.1218
– volume: 9
  year: 2003
  ident: B20
  article-title: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
  publication-title: Nat Med
  doi: 10.1038/nm863
– volume: 32
  start-page: S1042
  year: 2021
  ident: B107
  article-title: 1375p shr-1701, a novel bifunctional anti-Pd-L1/Tgf-βRii agent, for pretreated Recurrent/Refractory (R/R) gastric cancer (Gc): Data from a first-in-Human phase I study
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.08.1484
– volume: 50
  year: 2019
  ident: B35
  article-title: Transforming growth factor-B signaling in immunity and cancer
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.03.024
– volume: 378
  year: 2018
  ident: B62
  article-title: Atezolizumab for first-line treatment of metastatic nonsquamous nsclc
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1716948
– volume: 40
  year: 2022
  ident: B110
  article-title: Phase ii study of shr-1701 combined with famitinib in the treatment of advanced pancreatic cancer or biliary tract cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2022.40.4_suppl.568
– volume: 258
  year: 2020
  ident: B1
  article-title: Anti-angiogenesis: Opening a new window for immunotherapy
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.118163
– volume: 39
  year: 2021
  ident: B105
  article-title: Shr-1701, a bifunctional fusion protein targeting pd-L1 and tgf-B, for advanced nsclc with egfr mutations: Data from a multicenter phase 1 study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2021.39.15_suppl.9055
– volume: 32
  start-page: 12
  year: 2009
  ident: B40
  article-title: Tumor-derived tgf-beta mediates conversion of Cd4+Foxp3+ regulatory T cells in a murine model of pancreas cancer
  publication-title: J Immunother (Hagerstown Md 1997)
  doi: 10.1097/CJI.0b013e318189f13c
– volume: 19
  start-page: 2900
  year: 2018
  ident: B85
  article-title: Optimized expression and characterization of a novel fully human bispecific single-chain diabody targeting vascular endothelial growth Factor165 and programmed death-1 in pichia pastoris and evaluation of antitumor activity in vivo
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19102900
– volume: 19
  year: 2021
  ident: B61
  article-title: A phase I/Ii study to assess the safety and efficacy of pazopanib and pembrolizumab combination therapy in patients with advanced renal cell carcinoma
  publication-title: Clin Genitourinary Cancer
  doi: 10.1016/j.clgc.2021.04.007
– volume: 101
  year: 2003
  ident: B21
  article-title: Vegf inhibits T-cell development and may contribute to tumor-induced immune suppression
  publication-title: Blood
  doi: 10.1182/blood-2002-07-1956
– volume: 19
  year: 2018
  ident: B9
  article-title: Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (Javelin renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(18)30107-4
– volume: 38
  year: 2020
  ident: B55
  article-title: Phase Ib/Ii trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors
  publication-title: J Clin Oncol
  doi: 10.1200/jco.19.01598
– volume: 9
  start-page: ra19
  year: 2016
  ident: B33
  article-title: Tgf-B inhibits the activation and functions of nk cells by repressing the mtor pathway
  publication-title: Sci Signaling
  doi: 10.1126/scisignal.aad1884
– volume: 8
  year: 2020
  ident: B23
  article-title: Anti-vegf treatment enhances Cd8(+) T-cell antitumor activity by amplifying hypoxia
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.cir-19-0360
– volume: 22
  start-page: :7575
  year: 2021
  ident: B47
  article-title: Tgf-B signaling: From tissue fibrosis to tumor microenvironment
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22147575
– volume: 21
  start-page: 535
  year: 2021
  ident: B28
  article-title: Curcumin upregulates transforming growth factor-B1, its receptors, and vascular endothelial growth factor expressions in an in vitro human gingival fibroblast wound healing model
  publication-title: BMC Oral Health
  doi: 10.1186/s12903-021-01890-9
– volume: 12
  year: 2020
  ident: B53
  article-title: Pembrolizumab in combination with axitinib as first-line treatment for patients with renal cell carcinoma (Rcc): Evidence to date
  publication-title: Cancer Manage Res
  doi: 10.2147/cmar.s216605
– volume: 38
  year: 2020
  ident: B72
  article-title: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  doi: 10.1200/jco.19.02627
– volume: 63
  start-page: 48
  year: 2018
  ident: B15
  article-title: Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through Igg1 isotype immune effector stimulation
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2017.11.008
– volume: 33
  year: 2021
  ident: B87
  article-title: Insights into non-peptide small-molecule inhibitors of the pd-1/Pd-L1 interaction: Development and perspective
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2021.116038
– volume: 13
  year: 2017
  ident: B90
  article-title: Transforming growth factor-B: A therapeutic target for cancer
  publication-title: Hum Vaccines Immunother
  doi: 10.1080/21645515.2017.1327107
– volume: 8
  year: 2020
  ident: B98
  article-title: Bintrafusp Alfa, a bifunctional fusion protein targeting tgf-B and pd-L1, in advanced squamous cell carcinoma of the head and neck: Results from a phase I cohort
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000664
– volume: 9
  year: 2021
  ident: B91
  article-title: Safety and activity of the tgfβ receptor I kinase inhibitor galunisertib plus the anti-Pd-L1 antibody durvalumab in metastatic pancreatic cancer
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-002068
– volume: 2014
  year: 2014
  ident: B54
  article-title: Antitumor activity of lenvatinib (E7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models
  publication-title: J Thyroid Res
  doi: 10.1155/2014/638747
– volume: 40
  year: 2022
  ident: B83
  article-title: Efficacy, safety, and biomarker analysis of neoadjuvant Avelumab/Axitinib in patients (Pts) with localized renal cell carcinoma (Rcc) who are at high risk of relapse after nephrectomy (Neoavax)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2022.40.6_suppl.289
– volume: 5
  year: 2016
  ident: B4
  article-title: Regulation of myeloid cells by activated T cells determines the efficacy of pd-1 blockade
  publication-title: Oncoimmunology
  doi: 10.1080/2162402x.2016.1232222
– volume: 10
  year: 2018
  ident: B10
  article-title: Tgf-B in T cell biology: Implications for cancer immunotherapy
  publication-title: Cancers
  doi: 10.3390/cancers10060194
– volume: 32
  year: 2018
  ident: B89
  article-title: Small-molecule immune checkpoint inhibitors targeting pd-1/Pd-L1 and other emerging checkpoint pathways
  publication-title: BioDrugs Clin Immunother Biopharmaceut Gene Ther
  doi: 10.1007/s40259-018-0303-4
– volume: 10
  year: 2022
  ident: B74
  article-title: Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: Results from an open-label, multicenter phase 2 basket study
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2021-003831
– volume: 7
  year: 2016
  ident: B8
  article-title: Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
  publication-title: Nat Commun
  doi: 10.1038/ncomms12624
– volume: 35
  year: 2011
  ident: B38
  article-title: T Cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived tgf-B1 cytokine
  publication-title: Immunity
  doi: 10.1016/j.immuni.2011.04.019
– volume: 5
  year: 2019
  ident: B80
  article-title: Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.3343
– volume: 6
  start-page: 106
  year: 2018
  ident: B24
  article-title: Targeting Vegfr2 with ramucirumab strongly impacts effector/ activated regulatory T cells and Cd8(+) T cells in the tumor microenvironment
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-018-0403-1
– volume: 26
  year: 2014
  ident: B6
  article-title: Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.10.006
– volume: 8
  year: 2020
  ident: B99
  article-title: Bintrafusp Alfa, a bifunctional fusion protein targeting tgf-B and pd-L1, in patients with human papillomavirus-associated malignancies
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001395
– volume: 6
  start-page: 109
  year: 2018
  ident: B60
  article-title: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The checkmate 016 study
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-018-0420-0
– volume: 27
  year: 2021
  ident: B70
  article-title: Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (Rescue): A nonrandomized, open-label, phase ii trial
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.ccr-20-2571
– volume: 78
  year: 2018
  ident: B42
  article-title: Combined vegf and pd-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.can-17-2176
– volume: 29
  year: 2018
  ident: B50
  article-title: Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase iii, randomized atlas trial
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy454
– volume: 13
  year: 2012
  ident: B32
  article-title: Tgf-B is responsible for nk cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy
  publication-title: Nat Immunol
  doi: 10.1038/ni.2388
– volume: 32
  start-page: S995
  year: 2021
  ident: B108
  article-title: 1278p shr-1701, a bifunctional fusion protein targeting pd-L1 and tgf-B, as first-line therapy for pd-L1+ Advanced/Metastatic nsclc: Data from a clinical expansion cohort of a phase I study
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.08.1880
– volume: 160
  year: 1998
  ident: B18
  article-title: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa b activation in hemopoietic progenitor cells
  publication-title: J Immunol (Baltimore Md 1950)
  doi: 10.4049/jimmunol.160.3.1224
– volume: 21
  year: 2020
  ident: B71
  article-title: Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (Epoc1706): An open-label, single-arm, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(20)30271-0
– volume: 38
  year: 2020
  ident: B76
  article-title: Camrelizumab plus apatinib in patients with advanced cervical cancer (Clap): A multicenter, open-label, single-arm, phase ii trial
  publication-title: J Clin Oncol
  doi: 10.1200/jco.20.01920
– volume: 9
  year: 2020
  ident: B94
  article-title: Pan-tgfβ inhibition by Sar439459 relieves immunosuppression and improves antitumor efficacy of pd-1 blockade
  publication-title: Oncoimmunology
  doi: 10.1080/2162402x.2020.1811605
– volume: 212
  year: 2015
  ident: B22
  article-title: Vegf-a modulates expression of inhibitory checkpoints on Cd8+ T cells in tumors
  publication-title: J Exp Med
  doi: 10.1084/jem.20140559
– volume: 24
  year: 2020
  ident: B109
  article-title: Tgf-beta: A master immune regulator
  publication-title: Expert Opin Ther Targets
  doi: 10.1080/14728222.2020.1744568
– volume: 393
  year: 2019
  ident: B48
  article-title: Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (Immotion151): A multicentre, open-label, phase 3, randomised controlled trial
  publication-title: Lancet (London England)
  doi: 10.1016/s0140-6736(19)30723-8
– volume: 27
  year: 2021
  ident: B92
  article-title: First-in-Human phase I study of a next-generation, oral, tgfβ receptor 1 inhibitor, Ly3200882, in patients with advanced cancer
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
  doi: 10.1158/1078-0432.ccr-21-1504
– volume: 7
  year: 2019
  ident: B34
  article-title: Autocrine tgfβ is a survival factor for monocytes and drives immunosuppressive lineage commitment
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.cir-18-0310
– volume: 24
  year: 2018
  ident: B97
  article-title: Phase I trial of M7824 (Msb0011359c), a bifunctional fusion protein targeting pd-L1 and tgfβ, in advanced solid tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.ccr-17-2653
– volume: 38
  year: 2020
  ident: B69
  article-title: Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/jco.20.00808
– volume: 40
  year: 2022
  ident: B75
  article-title: Efficacy and safety of sintilimab plus anlotinib for pd-L1-Positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase ii trial
  publication-title: J Clin Oncol
  doi: 10.1200/jco.21.02091
– volume: 39
  year: 2021
  ident: B104
  article-title: Phase 1 study of shr-1701, a bifunctional fusion protein targeting pd-L1 and tgf-B, in patients with advanced solid tumors
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2021.39.15_suppl.2503
– volume: 193
  year: 2001
  ident: B30
  article-title: Differentiation of T regulatory cells by immature dendritic cells
  publication-title: J Exp Med
  doi: 10.1084/jem.193.2.f5
– volume: 102
  year: 2008
  ident: B45
  article-title: Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis
  publication-title: Circ Res
  doi: 10.1161/circresaha.107.167171
– volume: 8
  year: 2020
  ident: B79
  article-title: Apatinib plus camrelizumab (Anti-Pd1 therapy, shr-1210) for advanced osteosarcoma (Apfao) progressing after chemotherapy: A single-arm, open-label, phase 2 trial
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000798
– volume: 172
  year: 2013
  ident: B41
  article-title: Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (Vegfr2) induces synergistic anti-tumour effect in vivo
  publication-title: Clin Exp Immunol
  doi: 10.1111/cei.12069
– volume: 15
  year: 2020
  ident: B11
  article-title: Bintrafusp Alfa, a bifunctional fusion protein targeting tgf-B and pd-L1, in second-line treatment of patients with nsclc: Results from an expansion cohort of a phase 1 trial
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.03.003
– volume: 25
  year: 2020
  ident: B100
  article-title: Phase I study of the bifunctional fusion protein bintrafusp Alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort
  publication-title: Oncol
  doi: 10.1634/theoncologist.2020-0249
– volume: 386
  year: 2022
  ident: B73
  article-title: Lenvatinib plus pembrolizumab for advanced endometrial cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa2108330
– volume: 554
  year: 2018
  ident: B44
  article-title: Tgfβ attenuates tumour response to pd-L1 blockade by contributing to exclusion of T cells
  publication-title: Nature
  doi: 10.1038/nature25501
– volume: 9
  year: 2021
  ident: B86
  article-title: 427 efficacy and safety of Ak112, an anti-Pd-1/Vegf-a bispecific antibody, in patients with platinum-Resistant/Refractory epithelial ovarian cancer in a phase 1 study
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2021-SITC2021.427
– ident: B103
– volume: 62
  year: 2018
  ident: B36
  article-title: Role of T-bet, the master regulator of Th1 cells, in the cytotoxicity of murine Cd4(+) T cells
  publication-title: Microbiol Immunol
  doi: 10.1111/1348-0421.12586
– volume: 382
  year: 2020
  ident: B67
  article-title: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1915745
– volume: 9
  start-page: 741
  year: 2018
  ident: B14
  article-title: Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable tgfβ enhance the efficacy of cancer immunotherapy
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-02696-6
– volume: 219
  year: 2009
  ident: B46
  article-title: Transforming growth factor-beta 1 (Tgf-Beta1) induces angiogenesis through vascular endothelial growth factor (Vegf)-mediated apoptosis
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.21706
– volume: 120
  start-page: 196
  year: 2019
  ident: B43
  article-title: Pre- and post-operative anti-Pd-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
  publication-title: Br J Cancer
  doi: 10.1038/s41416-018-0297-1
– volume: 12
  year: 2021
  ident: B84
  article-title: A novel bispecific antibody targeting pd-L1 and vegf with combined anti-tumor activities
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.778978
SSID ssj0000650103
Score 2.379159
SecondaryResourceType review_article
Snippet Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF)...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 905520
SubjectTerms immunotherapy
Oncology
PD-1
review
TGF-β
tumor microenvironment
VEGF
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQDxUXBC2I5U-uxKF7MJt4bSfmRstuVxVFHBbUm-X4R1upclCbHngtHoRnYibOls0FLlxjO3FmHM83Gc83hLwFxO9kjJw52RRMVDIy6BmZ0NyCwW2sCOgoXnxWq6_i_FJe7pT6wjNhmR44C27mtIplrOY6ei6Qu0QiKqi4sljvxva7L9i8HWcq78ESCxjkuCR4YXoW24SMhZy_04WUWN57xw71dP0jjDk-IbljcpaPyaMBK9IPeY5PyIOQDsj-xRANPyRp_Sd5iuYj3WCIaBvpt8XZktrkZ-0NXZ8t2a-ftGtpSBvUMTR0V-zLR3b8aVrSnID14z2Fm9Ew1BilmHVCt1mTtC_tcfuUrJeL9emKDfUTmAOY0bFYa166OvKoVVUoX9ce5GdlFL6uYhDCct14ibFa13BeNrL0TRk8D1a7Qs-fkb3UpvCcUIz91V7NPQwVOpY1oBbAUYVz4G0FX07IbCtM4wZucSxxcW3Ax0DxGxS_QfGbLP4Jmd6P-J55Nf7S9wT1c98PGbH7C7BOzLBOzL_WyYQcbbVr4AvCsIhNob27NZiRhyStUk1INVL76InjlnS16bm49Vwhg86L_zHFl-QhvjX-OebqFdnrbu7Ca4A8XfOmX92_AXIZ_OA
  priority: 102
  providerName: Directory of Open Access Journals
Title Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
URI https://www.proquest.com/docview/2702179156
https://pubmed.ncbi.nlm.nih.gov/PMC9360509
https://doaj.org/article/c96f1f739fd24503850095726a5302a2
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYlgZBL6ZNumwYVemgOytqyJFuBUvrIbijd0sOm7M3IeiSBIDe7DiR_Kz-kv6kztjepIfTQiw-WxsYayfONRvMNIW8B8VsZAmdWVgkTuQwMegYmNDdgcCsjPDqKs-_q6Fh8XcjFXXp0P4Cre107rCd1vDzfv7q4_gAL_j16nGBvx6GOSEbI-b5OpOTgwG-CXcqxnsGsB_vdf1liUYMuVnmv4DbZwjxV8ArlwEy1bP4DCDo8QPmXRZo8Ig97KEk_drp_TB74-IRszfpg-VMS53e5VbQ78Q12itaB_jycTqiJblwv6Xw6Yb9vaFNTH09xCkBDc8Z-fGHvvu2ltMvPuj6g8DDq-xKkFJNS6DqpkraVP1bPyHxyOP98xPryCswCCmlYKDRPbRF40CpPlCsKl2SFkUG4Ig9eCMN15SSGcm3FeVrJ1FWpd9wbbROdPScbsY7-BaEYGiycyhyICh3SAkANwKzEWnDGvEtHZLwezNL21ONYAeO8BBcENVGiJkrURNlpYkT2biV-dbQb_-j7CfVz2w8Js9sb9fKk7NdfabUKacgzHRwXSIEjEVzmXBksm2T4iLxZa7eEBYZRExN9fbkqMWEPOVylGpF8oPbBG4ct8ey0perWmUKCnZf_LfmKbOOn4m4yVztko1le-tcAg5pqt90-gOt0ke62M_0PDWAI5w
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+targeting+of+VEGF+and%2For+TGF-%CE%B2+to+enhance+anti-PD-%28L%291+therapy%3A+The+evidence+from+clinical+trials&rft.jtitle=Frontiers+in+oncology&rft.au=Li%2C+Linwei&rft.au=Wen%2C+Qinglian&rft.au=Ding%2C+Ruilin&rft.date=2022-07-26&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=12&rft_id=info:doi/10.3389%2Ffonc.2022.905520&rft_id=info%3Apmid%2F35957885&rft.externalDocID=PMC9360509
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon